Experimental estimation of the radioprotective efficiency of recombinant flagellin

Abstract

The effect of prophylactic or therapeutic administration of domestic recombinant flagellin on the survival of mice exposed to lethal doses X-rays (LD60/30 – LD100/30) was studied. Studied different patterns of use recombinant flagellin in relation to the effects of radiation exposure: ± 15–30 min, 2 h, 24 h. It is shown that the greatest radioprotective effect of the drug manifests after its introduction for 15-30 min before irradiation. A single intraperitoneal injection of 1 mg/kg flagellin increased the survival rate of mice after irradiation of 7,5 and 8,5 Gy of 37 and 80%, respectively. The calculated value СД50/30 increased from 7,04±0,01 Gy (95% CI: 6,99; 7,10) in untreated mice to 11,7± 0,28 Gy (95% CI: 9,43; 14,1) in animals with the use of recombinant flagellin. 30-day survival of mice, when the drug is administered 15–30 min prior to irradiation of 8 Gy at a dose of 1 mg/kg increased to 53%, of 2 mg/kg up to 87% (p< 0,01). In the control group survived, 20% of mice. We also observed a significant modifying effect of flagellin on severity of radiation-induced weight loss in mice. The value Spearman R increased from –0,94 in irradiation control to –0,055 in mice that received injection of flagellin 15–30 min before X-rays (р< 0,001). It was also shown that mice tolerate flagellin intraperitoneal injection of 2 mg/kg. Significant side effects of the drug have not been identified. The obtained results confirm the prospects of further research aimed at developing flagellin- based medical countermeasures for radiation exposure.

Keywords

recombinant flagellin / radioprotective efficacy / X-radiation / mice / survival rate / therapeutic administration / preventive administration

References

[1] 30 лет после Чернобыля: патогенетические механизмы формирования соматической патологии, опыт медицинского сопровождения участников ликвидации последствий аварии на Чернобыльской атомной электростанции: монография / под ред. С.С. Алексанина. – СПб.: Политехника-принт, 2016. – 506 с.

[2] Аль-Шехадат, Р.И. Получение и изучение свойств рекомбинантного бактериального флагеллина / Р.И. Аль-Шехадат [и др.] // Хим. и биол. безопас. – 2012. – Спец. вып. – С. 109–116.

[3] Боровиков, В.П. Популярное введение в современный анализ данных в системе STATISTICA / В.П. Боровиков. – М.: Горячая линия – Телеком, 2013. – 288 с.

[4] Гребенюк, А.Н. Получение различных вариантов рекомбинантного флагеллина и оценка их радиозащитной эффективности / А.Н. Гребенюк [и др.]. // Вестн. Росс. военно-мед. акад. – 2013. – Т. 43, № 3. – С. 75–80.

[5] Гребенюк, А.Н. Практическое руководство по использованию медицинских средств противорадиационной защиты при чрезвычайных ситуациях и обеспечению ими аварийных медико-санитарных формирований и региональных аварийных центров / А.Н. Гребенюк [и др.]. – М.: Комментарий, 2015. – 304 с.

[6] Директива 2010/63/EU Европейского парламента и совета европейского союза по охране животных, используемых в научных целях. – СПб.: Rus-LASA «НП объединение специалистов по работе с лабораторными животными», рабочая группа по переводам и изданию тематической литературы, 2012. – 48 с.

[7] Лушников, Е.Ф. Современная лучевая патология человека: проблемы методологии исследований, этиологии, патогенеза и классификации / Е.Ф. Лушников, А.Ю. Абросимов. – Обнинск: ФГБУ МРНЦ Минздравсоцразвития России, 2012. – 236 с.

[8] Софронов, Г.А. Перспективные направления использования препаратов на основе рекомбинантного флагеллина / Г.А. Софронов [и др.].// Мед. акад. журн. – 2017. – Т. 17, №2. – С. 7–20.

[9] Burdelya, L.G. An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models / L.G. Burdelya [et al.]. // Science. – 2008. – Vol. 320, № 5873. – Р. 226–230.

[10] Carvalho, F.A. TLR5 activation induces secretory interleukin-1 receptor antagonist (sIL-1Ra) and reduces inflammasome- associated tissue damage / F.A. Carvalho [et al.] // Mucosal Immunol. – 2011. – Vol. 4, № 1. – Р. 102–111.

[11] Chen, H. Activation of Toll-like receptors by intestinal microflora reduces radiation-induced DNA damage in mice / H. Chen [et al.] // Mutat. Res. Genet. Toxicol. Environ. Mutagen. – 2014. – Vol. 774. – P. 22–28.

[12] Finney, D.J. The median lethal dose and its estimation / D.J. Finney // Arch. Toxicol. – 1985. – Vol. 56, № 4. – P. 215–218.

[13] Fushiki, S. Radiation hazards in children -lessons from Chernobyl, Three Mile Island and Fukushima / S. Fushiki // Brain Dev. – 2013. – Vol. 35, № 3. – Р. 220–227.

[14] Honko, A.N., Mizel S.B. Effects of flagellin on innate and adaptive immunity / A.N. Honko, S.B. Mizel // Immunol. Res. – 2005. – Vol. 33, № 1. – Р. 83–101.

[15] Jones, R.M. Flagellin administration protects gut mucosal tissue from irradiation-induced apoptosis via MKP-7 activity / R.M. Jones [et al.] // Gut. – 2011. – Vol. 60, № 5. – P. 648–657.

[16] Krivokrysenko, V.I. Identification of granulocyte colony- stimulating factor and interleukin-6 as candidate biomarkers of CBLB502 efficacy as a medical radiation countermeasure / V.I. Krivokrysenko [et al.] // J. Pharmacol. Exp. Ther. – 2012. – Vol. 343, № 2. – Р. 497–508.

[17] Li, W. CBLB502, an agonist of Toll-like receptor 5, has antioxidant and scavenging free radicals activities in vitro / W. Li [et6 al.] // Int. J. Biol. Macromol. – 2016. – Vol. 82. – P. 97-103.

[18] Prasanna, P.G. Normal tissue protection for improving radiotherapy: Where are the Gaps? / P.G. Prasanna [et al.] // Transl. Сancer Res. – 2012. – Vol. 1, № 1. – P. 35–48.

[19] Singh, V.K. Medical countermeasures for unwanted CBRN exposures: part II radiological and nuclear threats with review of recent countermeasure patents / V. Singh [et al.] // Expert Opin. Ther. Patents. – 2016. – Vol. 26, № 12. – P. 1399–1408.

[20] Takeda, K. Toll-like receptors / K. Takeda, T. Kaisho, S. Akira // Annu. Rev. Immunol. – 2003. – Vol. 21. – Р. 335–376.

[21] Toshkov, I.A. Mitigation of radiation-induced epithelial damage by the TLR5 agonist Entolimod in a mouse model of fractionated head and neck irradiation / I.A. Toshkov [et al.] Radiat. Res. – 2017. – Vol. 187, № 5. – P. 570–580.

[22] Vijay-Kumar, M. Flagellin treatment protects against chemicals, bacteria, viruses, and radiation / M. Vijay-Kumar [et al.] J. Immunol. – 2008. – Vol. 180, № 12. – P. 8280–8285.

[23] Wang, Z.D. Toll-like receptor 5 agonist protects mice from radiation pneumonitis and pulmonary fibrosis / Z.D. Wang [et al.] Asian. Pac. J. Cancer Prev. – 2012. – Vol. 13, № 9. – P. 4763-4767.

[24] Xiao, Y. Over-activation of TLR5 signaling by high-dose flagellin induces liver injury in mice / Y. Xiao [et al.] Cell Mol. Immunol. – 2015. – Vol. 12, № 6. – P. 729-742.

[25] Zhou, S.X. Toll-like receptor 5 agonist inhibition of growth of A549 lung cancer cells in vivo in a Myd88 dependent manner / S.X. Zhou [et al.] // Asian Pac. J. Cancer Prev. – 2012. – Vol.13, № 6. – P. 2807–2812.

RIGHTS & PERMISSIONS

Eco-Vector